Silence Therapeutics

SLN

Silence Therapeutics (AIM:SLN) is a biotechnology company that develops gene therapeutic technology based on RNA interference (RNAi). They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters in Hammersmith, London.

Silence Therapeutics has been a target of short sellers for a while. The current short interest of 4.86% is roughly at the average of the last 12 months (3.01%).